Search results
Dec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
- Pfizer and BioNTech Announce Positive Topline Data for mRNA ...
NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc....
- Pfizer and BioNTech Announce Phase 3 Trial Data Showing High ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc....
- Pfizer and BioNTech Announce Positive Topline Data for mRNA ...
Nov 18, 2020 · Pfizer and BioNTech update their promising COVID-19 vaccine result. Efficacy trial reaches endpoint and companies plan to soon submit data for emergency use authorizations in the United States and elsewhere. 18 Nov 2020. By Jon Cohen.
Aug 23, 2021 · For Immediate Release: August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19...
Jan 9, 2024 · Mainz, Germany, January 9, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) provided its full year 2024 revenue guidance as part of its outlined 2024 strategic...
Mar 11, 2024 · MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American...
